Plain-English translation of NCT06446154 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a phase II clinical trial testing as a second-line treatment for patients with advanced liver cancer (hepatocellular carcinoma) that cannot be surgically removed and who have already been treated with immune checkpoint inhibitors. works by blocking blood vessel growth in tumors, which can help slow cancer growth. The study will enroll 36 patients to see how well this medication works and how safe it is.
Currently, there are very few effective treatment options for people with advanced liver cancer whose tumors have stopped responding to immunotherapy. This medication has shown promise in treating other advanced cancers, so researchers want to test whether it could help liver cancer patients who need a different treatment approach.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will take as an oral medication (by mouth) as your second-line treatment for liver cancer. You will have regular clinic visits to check how well the treatment is working through scans and blood tests, and to monitor you for any side effects. The study will track your progress over time to see whether this medication helps slow your cancer growth.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China